Here's Why Nektar Therapeutics Is Skyrocketing 70% in November
After the company told investors that it plans to file for Food and Drug Administration approval for a drug that could disrupt the $12 billion market for opioid painkillers, Nektar Therapeutics (NASDAQ: NKTR) shares shot higher. However, that wasn't the only good news it's released so far this month. Management also unveiled impressive early-stage trial data for NKTR-214, a wholly owned immuno-oncology drug that's being studied for use alongside Bristol-Myers Squibb's (NYSE: BMY) multibillion-dollar drug Opdivo. Can Nektar Therapeutics' stock continue to climb?
In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes is joined by contributor Todd Campbell to explain what's next for Nektar Therapeutics and its investors. Also, they discuss why Loxo Oncology's (NASDAQ: LOXO) game-changing deal with Bayer AG (NASDAQOTH: BAYRY) disappointed investors and how the FDA approval of a new smart pill could change medicine forever.
A full transcript follows the video.
Source: Fool.com
Bristol-Myers Squibb Stock
Currently there is a rather positive sentiment for Bristol-Myers Squibb with 11 Buy predictions and 3 Sell predictions.
As a result the target price of 67 € shows a very positive potential of 63.91% compared to the current price of 40.88 € for Bristol-Myers Squibb.
